Antibiotics work by interfering with essential bacterial structures or biochemical processes, thereby inhibiting bacterial growth or causing bacterial death. Their effectiveness depends on selective toxicity, meaning that the drug targets features of bacterial cells that differ sufficiently from human cells to permit treatment at useful concentrations. Major antibiotic targets include bacterial cell wall synthesis, protein synthesis, DNA replication, RNA synthesis, and particular metabolic pathways.
Antibiotics can be bactericidal, meaning that they directly kill susceptible bacteria, or bacteriostatic, meaning that they primarily inhibit bacterial growth and allow host immune mechanisms to help clear the infection. This distinction is useful but not absolute because the effect of a drug can depend on concentration, bacterial species, growth conditions, infection site, and physiological state. Antibiotics are different from antiseptics and disinfectants, which are generally used on surfaces or tissues and are not designed to provide selective systemic treatment of bacterial infections. Antibiotics are also different from antiviral medicines, which target viruses and their replication processes.
Beta lactam antibiotics, including penicillins, cephalosporins, carbapenems, and related compounds, interfere with bacterial cell wall synthesis. Many bacteria possess a cell wall containing peptidoglycan, a strong polymer that helps maintain cellular shape and prevents osmotic rupture. Beta lactams bind to penicillin binding proteins involved in the final stages of peptidoglycan assembly and cross linking. When cell wall construction is disrupted, actively growing bacteria can become structurally unstable and may lyse. The precise response depends on bacterial species and physiological state.
Other antibiotics affect different aspects of cell envelope construction. Glycopeptide antibiotics such as vancomycin bind specific components of peptidoglycan precursors and interfere with cell wall formation, particularly in susceptible Gram positive bacteria. Because human cells do not possess peptidoglycan cell walls, these targets provide useful selective toxicity. Resistance can arise when bacteria modify drug targets, reduce drug access, or produce enzymes that inactivate particular antibiotics.
Many antibiotics interfere with bacterial protein synthesis by targeting bacterial ribosomes. Bacterial ribosomes are generally described as 70S particles composed of 30S and 50S subunits, whereas human cytosolic ribosomes are 80S, although human mitochondria possess ribosomes with bacterial evolutionary characteristics. Tetracyclines bind the 30S subunit and interfere with aminoacyl transfer RNA entry, while aminoglycosides interact with the 30S subunit and can disrupt accurate translation. Macrolides bind the 50S subunit and inhibit aspects of peptide elongation.
Other classes, including chloramphenicol and oxazolidinones, target different components or stages of bacterial translation. These drugs exploit structural and functional differences between bacterial and human protein synthesis. Because protein production is essential for growth, metabolism, repair, and reproduction, interference with translation can strongly impair bacterial survival. However, antibiotic activity depends on drug concentration, tissue penetration, bacterial physiology, and susceptibility mechanisms, so the same drug can have very different effects on different bacterial species.
Some antibiotics interfere directly with bacterial DNA replication or RNA synthesis. Fluoroquinolones target bacterial DNA gyrase and topoisomerase IV, enzymes that control DNA topology during replication and chromosome management. Inhibition of these enzymes can generate severe DNA damage and disrupt chromosome replication. Rifamycins such as rifampicin inhibit bacterial RNA polymerase, reducing transcription of RNA from DNA. Without accurate transcription, bacteria cannot produce the proteins and RNA molecules required for normal growth and metabolism.
Other antimicrobial agents interfere with specific metabolic pathways. Sulfonamides and trimethoprim, for example, inhibit successive steps in folate metabolism, a pathway bacteria use to synthesise important cellular compounds. Human cells obtain folate through dietary sources and use different biochemical pathways, creating a degree of selective toxicity. Blocking metabolic pathways can therefore inhibit bacterial multiplication without directly damaging the same pathway in human cells to the same extent.
Antibiotics can be classified by their molecular structure, target, mechanism, spectrum of activity, and pharmacological properties. Narrow spectrum antibiotics act against a relatively restricted group of bacteria, whereas broad spectrum antibiotics affect a wider range of organisms. Broad activity can be useful when the causative organism is unknown, but it can also disrupt susceptible members of the normal microbiota and exert broader selection pressure.
Antibiotic choice depends on the likely or confirmed pathogen, infection site, susceptibility profile, patient factors, allergies, drug interactions, organ function, and local resistance patterns. Pharmacokinetics describes what the body does to a drug, including absorption, distribution, metabolism, and excretion, while pharmacodynamics describes relationships between drug exposure and biological effect. Adequate drug concentrations must reach the infected tissue for treatment to work. Some antibiotics penetrate particular tissues poorly, while others are highly distributed. The appropriate dose and administration schedule therefore depend on both the microorganism and the drug's behaviour within the body.
Antibiotic treatment does not directly remove every bacterium from the body. It changes the competitive environment by inhibiting susceptible bacteria, allowing the immune system and other physiological processes to eliminate organisms that remain. Bacteriostatic drugs can be particularly dependent on host immunity because they primarily halt bacterial multiplication rather than causing immediate bacterial death. Bactericidal drugs can actively kill bacteria, although the distinction between bacteriostatic and bactericidal effects varies with conditions.
Antibiotic activity can also depend on whether bacteria are actively dividing. Some cell wall targeting drugs are especially effective against growing bacteria because cell wall synthesis is most active during growth. Dormant or slow growing bacteria can therefore be less susceptible to some mechanisms without necessarily possessing genetic resistance. Biofilms can further reduce effective treatment because bacteria within them may experience altered metabolic states and protective extracellular material.
Antibiotics do not work against every infectious disease because their targets are specific to susceptible microorganisms. Bacterial species differ in cell wall structure, ribosomes, metabolic pathways, membrane properties, and resistance mechanisms. Gram positive and Gram negative bacteria, for example, differ substantially in their cell envelope architecture, affecting drug penetration and susceptibility. Some bacteria naturally lack particular targets or have intrinsic resistance mechanisms.
Antibiotics can also produce adverse effects because selective toxicity is not absolute and because treatment can affect beneficial microorganisms. Disruption of the intestinal microbiota can produce gastrointestinal symptoms and create ecological opportunities for certain organisms to proliferate. Severe allergic reactions are possible with some drugs, and individual antibiotics have specific toxicities or interactions. These risks are balanced against the benefits of treating a genuine bacterial infection. Appropriate antibiotic selection therefore involves identifying the pathogen when possible, choosing a drug with a suitable target and susceptibility profile, achieving adequate exposure, and limiting unnecessary treatment.
A common misconception is that stronger antibiotics are always better. Effectiveness depends on whether the organism is susceptible and whether adequate concentrations reach the infection site, not simply on how broadly or intensely a drug acts. Another misconception is that antibiotics kill bacteria immediately. Some inhibit growth and rely substantially on immune clearance, while others require time and sustained exposure to produce their full effect. Antibiotic mechanisms also explain why resistance develops.
Bacteria can alter targets, destroy or modify drugs, reduce permeability, increase efflux, or use alternative metabolic pathways. The scientific study of antibiotic action therefore combines microbiology, molecular biology, pharmacology, physiology, and evolutionary biology. Understanding the specific cellular target of each antibiotic class is essential for predicting activity, adverse effects, resistance mechanisms, drug interactions, and appropriate clinical use.
